ANANDA Scientific Announces FDA approval of the IND for the Clinical Trial on the Treatment of Opioid Use Disorder (OUD)
ANANDA Scientific Inc., (a biotech pharma company) today announced approval by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder. The study will be done at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220104005104/en/
(Photo: Business Wire)
“This is the fourth IND approval for our investigational drug Nantheia™ product line, and it further re-enforces our vision of developing CBD as a therapeutic for a number of key indications. This clinical study at UCLA is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need,” said Sohail R. Zaidi, ANANDA’s Chief Executive Officer. “We are excited to be working with the UCLA team and look forward to this trial advancing.”
This trial is being led by principal investigators Edythe London, Ph.D., Distinguished Professor of Psychiatry and Biobehavioral Sciences as well as Molecular and Medicinal Pharmacology at the Jane and Terry Semel Institute at David Geffen School of Medicine UCLA, and Richard De La Garza II, Ph.D ., Professor of Psychiatry and Biobehavioral Sciences at the Jane and Terry Semel Institute at David Geffen School of Medicine UCLA. Funding for this trial is from the National Institute on Drug Abuse (NIDA). (Clinical Trials.gov Identifier: NCT03787628 )
“The approval of the IND for this important clinical trial is a key milestone for our ongoing research into therapeutic alternatives for opioid use disorder and reversal of the effects of the opioid epidemic,” said Dr. London.
“With the IND approved we are now moving quickly to get the trial under way,” said Dr. De La Garza.
ABOUT ANANDA SCIENTIFIC
ANANDA is a leading research-focused biotech company pioneering high-caliber clinical studies evaluating therapeutic indications such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder. The company employs patented delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd. Jerusalem, Israel) to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality pharmaceutical products. Consistent with its strong research-based data, the company also has a growing pipeline of nutraceutical over-the-counter products. The company has successfully launched these products in the US, Australia, and the UK, with expansion into additional markets such as the EU, China, Africa, and other countries in Asia. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its technology portfolio.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005104/en/
Contact information
ANANDA Scientific Media Relations | Christopher Moore | 813 326 4265 | media@anandascientific.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Society Awards8.1.2026 19:26:00 EET | Press release
Today, the Awards Committee of SPIE, the international society for optics and photonics, announced the recipients of its prestigious annual awards. Honoring transformative advancements across a range of professional areas — including medicine, astronomy, lithography, optical metrology, optical design, and community leadership — the Society's awards recognize technical accomplishments as well as committed service to SPIE and support of its organizational mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108227351/en/ SPIE, the international society for optics and photonics, awarded their Gold Medal to Maryellen Giger (pictured here with her team) for pioneering work in computer-aided diagnosis and image analysis/AI, significant impact on clinical translation, and supporting the next generation of medical-imaging scientists and the SPIE community. SPIE Gold Medal: Maryellen Giger For pioneering work in computer-aided
PUMA Appoints Nadia Kokni as Vice President Global Brand Marketing8.1.2026 17:30:00 EET | Press release
Sports company PUMA has appointed Nadia Kokni as Vice President, Global Brand Marketing, effective January 1, 2026. Nadia joins PUMA’s global leadership team and reports directly to Chief Brand Officer Maria Valdes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108099913/en/ Sports company PUMA has appointed Nadia Kokni as Vice President, Global Brand Marketing, effective January 1, 2026. Nadia joins PUMA’s global leadership team and reports directly to Chief Brand Officer Maria Valdes. In her new role as PUMA’s most senior global marketing leader, Nadia will oversee brand marketing strategy, brand marketing creative direction, integrated marketing and communication globally. Her appointment comes as PUMA accelerates its global brand ambition and sharpens storytelling around its product icons and innovation pipeline. Nadia brings deep international experience shaping and transforming leading global brands across the spor
Xsolla Kicks Off Two Weeks of Industry Programming, Community Events, and Expanding Support for Global Developers Across the UK at the Industry’s Biggest Winter Event8.1.2026 17:00:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announces a comprehensive program of events and activations across the United Kingdom taking place from January 10 to 22, 2026. This coordinated programming schedule reflects Xsolla’s continued investment in the UK and European games ecosystem. Capitalizing on a pivotal moment in the global games calendar, Xsolla is bringing developers, partners, and creators together through partnerships, live events, thought leadership, and community building. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108943976/en/ (Graphic: Xsolla) “Pocket Gamer Connects London brings together one of the most diverse and forward-thinking communities in the mobile global games industry,” said Berkley Egenes, Chief Marketing and Growth Officer. “We’re here to build all the things for the video game industry by helping developers turn grea
Golub Capital Continues Strong Track Record of Consistent Results in 20258.1.2026 17:00:00 EET | Press release
Golub Capital delivered another year of “good boring,” consistent results for its stakeholders in 2025, aided by its commitment to specialization. “We have long believed that specialization is a key source of competitive advantage for Golub Capital,” said David Golub, President of the Firm. “The past year validated this. Our deep relationships, scale and expertise enabled us to continue delivering strong results for investors, sponsors, portfolio companies and our team despite a muted M&A environment and high levels of credit stress across the private equity ecosystem. We are grateful for our clients’ trust and remain committed to building long-term, win-win partnerships that endure through market cycles.” 2025 Highlights, based on preliminary results:1 Delivering strong credit performance, record fundraising and continued leadership in sponsor finance Closed $25+ billion in financing commitments in 2025 to support existing portfolio companies and new platforms across a broad range of
AMRA Medical Introduces AMRA® BCP Scan in the Netherlands Through a Strategic Partnership with Prescan, a National Preventative Health Leader8.1.2026 16:31:00 EET | Press release
AMRA Medical, the global leader in MRI-based fat distribution and muscle composition analytics, alongside Dutch preventative healthcare leader Prescan, are pleased to announce the official launch of our cutting-edge AMRA® BCP Scan service, powered by AMRA® Profiler (CE, NB 2862), in the Netherlands. The launch, which marks BCP Scan’s third new market entry of 2025 (Sweden & Germany), expands the availability of our service within the EU into the Netherlands through an exclusive partnership with Prescan, an independent health & wellness clinic in Baarn which specializes in preventive health screenings and care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108381985/en/ AMRA® BCP Scan available at Prescan AMRA’s CEO, Olof Dahlqvist Leinhard, stated, “This is another important step in bringing our mission of driving scientific breakthroughs into the clinic by enabling deeper understanding of health and disease through MRI-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom